Targeting PKCδ-mediated topoisomerase IIΒ overexpression subverts the differentiation block in a retinoic acid-resistant APL cell line

Leukemia

Volumn 24, Issue 4, 2010, Pages 729-739

  McNamara, S ^a   Nichol, J N ^a   Wang, H ^b   Miller Jr , W H ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Acute promyelocytic leukemia; Protein kinase C delta; Resistance; Retinoic acid; Topoisomerase II beta

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN; CYTOCHROME P450 26A1; DNA TOPOISOMERASE (ATP HYDROLYSING); GLYCOPROTEIN P 15095; PROTEIN KINASE C DELTA; RETINOIC ACID; RETINOIC ACID INDUCIBLE PROTEIN I; TOPOISOMERASE II BETA; UNCLASSIFIED DRUG;

ARTICLE; CANCER RESISTANCE; CELL DIFFERENTIATION; CELL NUCLEUS INCLUSION BODY; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME STABILITY; GENE TARGETING; GENETIC TRANSCRIPTION; GRANULOCYTE; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING;

EID: 77950925303     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.27     Document Type: Article

References (68)

1. de The H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 1991; 66: 675-684.
2. Kakizuka A, Miller Jr WH, Umesono K, Warrell Jr RP, Frankel SR, Murty VV et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 1991; 66: 663-674.
3. Pandolfi PP, Grignani F, Alcalay M, Mencarelli A, Biondi A, LoCoco F et al. Structure and origin of the acute promyelocytic leukemia myl/RAR alpha cDNA and characterization of its retinoid-binding and transactivation properties. Oncogene 1991; 6: 1285-1292.
4. Fenaux P, Le Deley MC, Castaigne S, Archimbaud E, Chomienne C, Link H et al. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood 1993; 82: 3241-3249.
5. Cornic M, Chomienne C. Induction of retinoid resistance by all-trans retinoic acid in acute promyelocytic leukemia after remission. Leuk Lymphoma 1995; 18: 249-257.
6. Duprez E, Ruchaud S, Houge G, Martin-Thouvenin V, Valensi F, Kastner P et al. A retinoid acid 'resistant' t(15;17) acute promyelocytic leukemia cell line: isolation, morphological, immunological, and molecular features. Leukemia 1992; 6: 1281-1287.
7. Imaizumi M, Suzuki H, Yoshinari M, Sato A, Saito T, Sugawara A et al. Mutations in the E-domain of RAR portion of the PML/RAR chimeric gene may confer clinical resistance to all-trans retinoic acid in acute promyelocytic leukemia. Blood 1998; 92: 374-382.
8. Ding W, Li YP, Nobile LM, Grills G, Carrera I, Paietta E et al. Leukemic cellular retinoic acid resistance and missense mutations in the PML-RARalpha fusion gene after relapse of acute promye-locytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapy. Blood 1998; 92: 1172-1183.
9. Marasca R, Zucchini P, Galimberti S, Leonardi G, Vaccari P, Donelli A et al. Missense mutations in the PML/RARalpha ligand binding domain in ATRA-resistant As(2)O(3) sensitive relapsed acute promyelocytic leukemia. Haematologica 1999; 84: 963-968.
10. Zhou DC, Kim SH, Ding W, Schultz C, Warrell Jr RP, Gallagher RE. Frequent mutations in the ligand-binding domain of PML-RARalpha after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo. Blood 2002; 99: 1356-1363.
11. Rosenauer A, Raelson JV, Nervi C, Eydoux P, DeBlasio A, Miller Jr WH. Alterations in expression, binding to ligand and DNA, and transcriptional activity of rearranged and wild-type retinoid receptors in retinoid-resistant acute promyelocytic leukemia cell lines. Blood 1996; 88: 2671-2682.
12. Shao W, Benedetti L, Lamph WW, Nervi C, Miller Jr WH. A retinoid-resistant acute promyelocytic leukemia subclone expresses a dominant negative PML-RAR alpha mutation. Blood 1997; 89: 4282-4289.
13. McNamara S, Wang H, Hanna N, Miller Jr WH. Topoisomerase II{beta} negatively modulates RAR{alpha} function-a novel mechanism of retinoic acid resistance. Mol Cell Biol 2008; 28: 2066-2077.
14. Austin CA, Marsh KL. Eukaryotic DNA topoisomerase II beta. Bioessays 1998; 20: 215-226.
15. Dong KC, Berger JM. Structural basis for gate-DNA recognition and bending by type IIA topoisomerases. Nature 2007; 450: 1201-1205.
16. Chen AY, Liu LF. DNA topoisomerases: essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol 1994; 34: 191-218.
17. Cardenas ME, Gasser SM. Regulation of topoisomerase II by phosphorylation: a role for casein kinase II. J Cell Sci 1993; 104 (Part 2): 219-225.
18. Aoyama M, Grabowski DR, Isaacs RJ, Krivacic KA, Rybicki LA, Bukowski RM et al. Altered expression and activity of topoisome-rases during all-trans retinoic acid-induced differentiation of HL-60 cells. Blood 1998; 92: 2863-2870.
19. Mirski SE, Sparks KE, Friedrich B, Kohler M, Mo YY, Beck WT et al. Topoisomerase II binds importin alpha isoforms and exportin/CRM1 but does not shuttle between the nucleus and cytoplasm in proliferating cells. Exp Cell Res 2007; 313: 627-637.
20. Cote S, Zhou D, Bianchini A, Nervi C, Gallagher RE, Miller Jr WH. Altered ligand binding and transcriptional regulation by mutations in the PML/RARalpha ligand-binding domain arising in retinoic acid-resistant patients with acute promyelocytic leukemia. Blood 2000; 96: 3200-3208.
21. Diaz Z, Mann KK, Marcoux S, Kourelis M, Colombo M, Komarnitsky PB et al. A novel arsenical has antitumor activity toward As2O3-resistant and MRP1/ABCC1-overexpressing cell lines. Leukemia 2008; 22: 1853-1863.
22. Momparler RL, Dore BT, Momparler LF. Effect of 5-aza-2-deoxycytidine and retinoic acid on differentiation and c-myc expression in HL-60 myeloid leukemic cells. Cancer Lett 1990; 54: 21-28.
23. Yoshida K, Yamaguchi T, Shinagawa H, Taira N, Nakayama KI, Miki Y. Protein kinase C delta activates topoisomerase IIalpha to induce apoptotic cell death in response to DNA damage. Mol Cell Biol 2006; 26: 3414-3431.
24. Mischak H, Kolch W, Goodnight J, Davidson WF, Rapp U, Rose-John S et al. Expression of protein kinase C genes in hemopoietic cells is cell-type-and B cell-differentiation stage specific. J Immunol 1991; 147: 3981-3987.
25. Kambhampati S, Li Y, Verma A, Sassano A, Majchrzak B, Deb DK et al. Activation of protein kinase C delta by all-trans-retinoic acid. J Biol Chem 2003; 278: 32544-32551. (Pubitemid 37055692)
26. del Rincon SV, Guo Q, Morelli C, Shiu HY, Surmacz E, Miller WH. Retinoic acid mediates degradation of IRS-1 by the ubiquitin-proteasome pathway, via a PKC-dependant mechanism. Onco-gene 2004; 23: 9269-9279.
27. Gschwendt M, Muller HJ, Kielbassa K, Zang R, Kittstein W, Rincke G et al. Rottlerin, a novel protein kinase inhibitor. Biochem Biophys Res Commun 1994; 199: 93-98.
28. Keenan C, Goode N, Pears C. Isoform specificity of activators and inhibitors of protein kinase C gamma and delta. FEBS Lett 1997; 415: 101-108. (Pubitemid 27402058)
29. Frasch SC, Henson PM, Kailey JM, Richter DA, Janes MS, Fadok VA et al. Regulation of phospholipid scramblase activity during apoptosis and cell activation by protein kinase Cdelta. J Biol Chem 2000; 275: 23065-23073.
30. Zhao KW, Li X, Zhao Q, Huang Y, Li D, Peng ZG et al. Protein kinase Cdelta mediates retinoic acid and phorbol myristate acetate-induced phospholipid scramblase 1 gene expression: its role in leukemic cell differentiation. Blood 2004; 104: 3731-3738.
31. Kaur S, Parmar S, Smith J, Katsoulidis E, Li Y, Sassano A et al. Role of protein kinase C-delta (PKC-delta) in the generation of the effects of IFN-alpha in chronic myelogenous leukemia cells. Exp Hematol 2005; 33: 550-557.
32. Kin Y, Shibuya M, Maru Y. Inhibition of protein kinase C delta has negative effect on anchorage-independent growth of BCR-ABL-transformed Rat1 cells. Leuk Res 2001; 25: 821-825.
33. Liao YF, Hung YC, Chang WH, Tsay GJ, Hour TC, Hung HC et al. The PKC delta inhibitor, rottlerin, induces apoptosis of haematopoietic cell lines through mitochondrial membrane depolarization and caspases' cascade. Life Sci 2005; 77: 707-719.
34. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000; 351 (Part 1): 95-105.
35. Kontny E, Kurowska M, Szczepanska K, Maslinski W. Rottlerin, a PKC isozyme-selective inhibitor, affects signaling events and cytokine production in human monocytes. J Leukoc Biol 2000; 67: 249-258.
36. Martiny-Baron G, Kazanietz MG, Mischak H, Blumberg PM, Kochs G, Hug H et al. Selective inhibition of protein kinase C isozymes by the indolocarbazole Go 6976. J Biol Chem 1993; 268: 9194-9197.
37. Ackerman P, Glover CV, Osheroff N. Phosphorylation of DNA topoisomerase II by casein kinase II: modulation of eukaryotic topoisomerase II activity in vitro. Proc Natl Acad Sci USA 1985; 82: 3164-3168.
38. Marini JC, Miller KG, Englund PT. Decatenation of kinetoplast DNA by topoisomerases. J Biol Chem 1980; 255: 4976-4979.
39. Koken MH, Puvion-Dutilleul F, Guillemin MC, Viron A, Linares-Cruz G, Stuurman N et al. The t(15;17) translocation alters a nuclear body in a retinoic acid-reversible fashion. EMBO J 1994; 13: 1073-1083.
40. Heck MM, Hittelman WN, Earnshaw WC. In vivo phosphorylation of the 170-kDa form of eukaryotic DNA topoisomerase II. Cell cycle analysis. J Biol Chem 1989; 264: 15161-15164.
41. Kimura K, Nozaki N, Saijo M, Kikuchi A, Ui M, Enomoto T. Identification of the nature of modification that causes the shift of DNA topoisomerase II beta to apparent higher molecular weight forms in the M phase. J Biol Chem 1994; 269: 24523-24526.
42. Burden DA, Sullivan DM. Phosphorylation of the alpha-and beta-isoforms of DNA topoisomerase II is qualitatively different in interphase and mitosis in Chinese hamster ovary cells. Biochemistry 1994; 33: 14651-14655.
43. Wells NJ, Addison CM, Fry AM, Ganapathi R, Hickson ID. Serine 1524 is a major site of phosphorylation on human topoisomerase II alpha protein in vivo and is a substrate for casein kinase II in vitro. J Biol Chem 1994; 269: 29746-29751.
44. Grozav AG, Chikamori K, Kozuki T, Grabowski DR, Bukowski RM, Willard B et al. Casein kinase I delta/epsilon phosphorylates topoisomerase IIalpha at serine-1106 and modulates DNA cleavage activity. Nucleic Acids Res 2009; 37: 382-392.
45. Li H, Wang Y, Liu X. Plk1-dependent phosphorylation regulates functions of DNA topoisomerase IIalpha in cell cycle progression. J Biol Chem 2008; 283: 6209-6221.
46. Chikamori K, Grabowski DR, Kinter M, Willard BB, Yadav S, Aebersold RH et al. Phosphorylation of serine 1106 in the catalytic domain of topoisomerase II alpha regulates enzymatic activity and drug sensitivity. J Biol Chem 2003; 278: 12696-12702.
47. Grabowski DR, Holmes KA, Aoyama M, Ye Y, Rybicki LA, Bukowski RM et al. Altered drug interaction and regulation of topoisomerase IIbeta: potential mechanisms governing sensitivity of HL-60 cells to amsacrine and etoposide. Mol Pharmacol 1999; 56: 1340-1345.
48. Buschmann T, Potapova O, Bar-Shira A, Ivanov VN, Fuchs SY, Henderson S et al. Jun NH2-terminal kinase phosphorylation of p53 on Thr-81 is important for p53 stabilization and transcriptional activities in response to stress. Mol Cell Biol 2001; 21: 2743-2754.
49. Okazaki K, Sagata N. The Mos/MAP kinase pathway stabilizes c-Fos by phosphorylation and augments its transforming activity in NIH 3T3 cells. EMBO J 1995; 14: 5048-5059.
50. Radominska-Pandya A, Chen G, Czernik PJ, Little JM, Samokyszyn VM, Carter CA et al. Direct interaction of all-trans-retinoic acid with protein kinase C (PKC). Implications for PKC signaling and cancer therapy. J Biol Chem 2000; 275: 22324-22330.
51. Yen A, Roberson MS, Varvayanis S, Lee AT. Retinoic acid induced mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase-dependent MAP kinase activation needed to elicit HL-60 cell differentiation and growth arrest. Cancer Res 1998; 58: 3163-3172.
52. Miranda MB, McGuire TF, Johnson DE. Importance of MEK-1/-2 signaling in monocytic and granulocytic differentiation of myeloid cell lines. Leukemia 2002; 16: 683-692.
53. Alsayed Y, Uddin S, Mahmud N, Lekmine F, Kalvakolanu DV, Minucci S et al. Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to all-trans-retinoic acid. J Biol Chem 2001; 276: 4012-4019.
54. Xu K, Chang CM, Gao H, Shu HK. Epidermal growth factor-dependent cyclooxygenase-2 induction in gliomas requires protein kinase C-delta. Oncogene 2009; 28: 1410-1420.
55. Vey N, Mozziconacci MJ, Groulet-Martinec A, Debono S, Finetti P, Carbuccia N et al. Identification of new classes among acute myelogenous leukaemias with normal karyotype using gene expression profiling. Oncogene 2004; 23: 9381-9391.
56. Gutierrez NC, Ocio EM, de Las Rivas J, Maiso P, Delgado M, Ferminan E et al. Gene expression profiling of B lymphocytes and plasma cells from Waldenstrom's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals. Leukemia 2007; 21: 541-549.
57. McKenna SL, West RR, Whittaker JA, Padua RA, Holmes JA. Topoisomerase II alpha expression in acute myeloid leukaemia and its relationship to clinical outcome. Leukemia 1994; 8: 1498-1502.
58. Lage H, Helmbach H, Dietel M, Schadendorf D. Modulation of DNA topoisomerase II activity and expression in melanoma cells with acquired drug resistance. Br J Cancer 2000; 82: 488-491.
59. Herzog CE, Holmes KA, Tuschong LM, Ganapathi R, Zwelling LA. Absence of topoisomerase IIbeta in an amsacrine-resistant human leukemia cell line with mutant topoisomerase IIalpha. Cancer Res 1998; 58: 5298-5300.
60. Buzdar AU. Topoisomerase IIalpha gene amplification and response to anthracycline-containing adjuvant chemotherapy in breast cancer. J Clin Oncol 2006; 24: 2409-2411.
61. Mandelli F, Diverio D, Avvisati G, Luciano A, Barbui T, Bernasconi C et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood 1997; 90: 1014-1021.
62. Afonja O, Raaka BM, Huang A, Das S, Zhao X, Helmer E et al. RAR agonists stimulate SOX9 gene expression in breast cancer cell lines: evidence for a role in retinoid-mediated growth inhibition. Oncogene 2002; 21: 7850-7860.
63. Duprez E, Wagner K, Koch H, Tenen DG. C/EBPbeta: a major PML-RARA-responsive gene in retinoic acid-induced differentiation of APL cells. EMBO J 2003; 22: 5806-5816.
64. Oh Y, Gucev Z, Ng L, Muller HL, Rosenfeld RG. Antiproliferative actions of insulin-like growth factor binding protein (IGFBP)-3 in human breast cancer cells. Prog Growth Factor Res 1995; 6: 503-512.
65. Grolleau A, Wietzerbin J, Beretta L. Defect in the regulation of 4E-BP1 and 2, two repressors of translation initiation, in the retinoid acid resistant cell lines, NB4-R1 and NB4-R2. Leukemia 2000; 14: 1909-1914.
66. Perissi V, Aggarwal A, Glass CK, Rose DW, Rosenfeld MG. A corepressor/coactivator exchange complex required for transcrip-tional activation by nuclear receptors and other regulated transcription factors. Cell 2004; 116: 511-526.
67. Chen Y, Hu X, Wei LN. Molecular interaction of retinoic acid receptors with coregulators PCAF and RIP140. Mol Cell Endocrinol 2004; 226: 43-50.
68. Zhao HL, Ueki N, Marcelain K, Hayman MJ. The Ski protein can inhibit ligand induced RARalpha and HDAC3 degradation in the retinoic acid signaling pathway. Biochem Biophys Res Commun 2009; 383: 119-124.